Internal Medicine, Pulmonary Disease · St Petersburg, FL
NPI
1114033453
Since 2006
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
1075 9th Ave N
St Petersburg, FL, 33705
Phone (727) 895-5864
Groups this clinician bills Medicare through
Medicare paid, 2024
$769K
27,869 services
Medicare patients, 2024
157
Average age 74
Drug cost, 2024
$4.6M
2,670 prescriptions
Company payments, 2025
$2,458
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael Newan was code J2357 (injection, omalizumab, 5 mg), 11,771 times for 21 patients. In total Michael Newan billed 27,869 services in 23 codes, and Medicare paid $769K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2357 Injection, omalizumab, 5 mg | Office | 11,771 | 21 | $29.01 | $341K |
| J2356 Injection, tezepelumab-ekko, 1 mg | Office | 5,670 | 11 | $14.27 | $81K |
| 96372 Injection Administration | Office | 1,272 | 65 | $10.47 | $13K |
| J0517 Injection, benralizumab, 1 mg | Office | 900 | 11 | $130.91 | $118K |
| 95004 Test - Miscellaneous | Office | 880 | 22 | $2.87 | $2,526 |
| 94618 Pulmonary Function Testing | Office | 622 | 153 | $25.13 | $16K |
| 99214 Office E&M - Established | Office | 592 | 147 | $94.56 | $56K |
| 94640 Treatment - Miscellaneous | Office | 115 | 115 | $5.79 | $666 |
| 94727 Pulmonary Function Testing | Office | 115 | 115 | $32.87 | $3,780 |
| 94729 Pulmonary Function Testing | Office | 115 | 115 | $41.14 | $4,731 |
| 94060 Pulmonary Function Testing | Office | 115 | 115 | $27.98 | $3,218 |
| 94200 Pulmonary Function Testing | Office | 115 | 115 | $10.87 | $1,250 |
| 99215 Office E&M - Established | Office | 17 | 13 | $141.60 | $2,407 |
| 99205 Office E&M - New | Office | 16 | 16 | $162.79 | $2,605 |
By year: 2022 $1.6M for 56,735 services; 2023 $1.9M for 70,577 services; 2024 $769K for 27,869 services.
Medicare prescription drug claims, 2024
In 2024, the drug Michael Newan prescribed most often to Medicare patients was Xolair (Omalizumab), with 470 prescriptions and refills. In total Michael Newan wrote 2,670 Medicare prescriptions that cost $4.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Xolair Omalizumab | 470 | 470 | 39 | $3.6M |
| Prednisone Generic | 268 | 328 | 124 | $1,085 |
| Montelukast Sodium Generic | 188 | 552 | 62 | $1,963 |
| Breo Ellipta Fluticasone/Vilanterol | 130 | 264 | 38 | $103K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 122 | 140 | 50 | $2,166 |
| Azithromycin Generic | 111 | 111 | 69 | $780 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 82 | 188 | 25 | $121K |
| Fluticasone Propionate Generic | 71 | 198 | 30 | $2,225 |
| Clonazepam Generic | 54 | 127 | 18 | $794 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 52 | 97 | 17 | $61K |
| Tezspire Tezepelumab-Ekko | 40 | 40 | Under 11 | $169K |
| Nucala Mepolizumab | 39 | 39 | Under 11 | $152K |
| Fasenra Benralizumab | 39 | 67 | Under 11 | $245K |
| Symbicort Budesonide/Formoterol Fumarate | 35 | 80 | 12 | $18K |
| Simvastatin Generic | 35 | 105 | Under 11 | $360 |
Brand drugs: - claims; generic drugs: 1,545 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael Newan $2,458 ($2,458 in general payments such as food, travel and fees) from 13 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $600.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 26 | $600 |
| GlaxoSmithKline, LLC. GSK | 22 | $534 |
| Jazz Pharmaceuticals Inc. JAZZ | 9 | $329 |
| Regeneron Healthcare Solutions, Inc. REGN | 8 | $250 |
| Genentech USA, Inc. ROG.SW | 11 | $228 |
| Amgen Inc. AMGN | 7 | $202 |
| Harmony Biosciences LLC HRMY | 7 | $154 |
| Novartis Pharmaceuticals Corporation NVS | 2 | $47.42 |
| Insmed, Inc. INSM | 2 | $31.81 |
| Pulmonx Corporation LUNG | 1 | $22.13 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.